CancerGuide Diagnostics™  is a life science company focused on development and commercialization of novel molecular diagnostic assays that enable oncologists and their patients to make individualized treatment decisions.

To the pharmaceutical and biotech industries, CancerGuide™ offers "Biomarker Progression", the first fully integrated biomarker development to commercialization capability.  The suite of companion diagnostic services includes clinical-grade test development, clinical trial protocol/design support, and bioinformatics/testing/profiling to enhance your biomarker strategy at any stage of preclinical and clinical development.

CancerGuide's proprietary methods enable the development or enhancement of highly accurate therapeutic response assays, very early in the development cycle. Moreover, aided by its comprehensive development and commercialization agreement with Laboratory Corporation of America® Holdings (LabCorp®), CancerGuide provides an innovative development-to-commercial market platform for translating emerging molecular oncology diagnostic technologies into clinical-grade tests on the market.

Combining these custom assays and our existing library of signatures allows us to analyze large tumor repositories for response to multiple therapies and thus the rational selection of market entry strategies, new indications for approved compounds, and effective drug combinations.

At CancerGuide your biomarkers can evolve and progress through clinical development using a whole genome measurement approach so that in the event that the original structure does not perform well as a biomarker, there is still an opportunity for future discovery from the dataset.

CancerGuide is committed to bringing novel personalized medicine clinical products to the clinic, so that those living with cancer are directed to the therapy that has the highest probability of success.